A lung adenocarcinoma patient with ROS1 fusion and NBN germline mutation achieves long progression-free survival from sintilimab combined with niraparib after failure of ROS1 inhibitors: a case report

BACKGROUND: Lung cancer is a malignant tumor with high morbidity and mortality worldwide. At present, the main treatment methods for patients with advanced non-small cell lung cancer (NSCLC) include molecular targeted therapy and immunotherapy. The efficacy rate of immune checkpoint inhibitor (ICI)...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Fangye, Xiao, Chunmei, Sun, Weijie, He, Yuange, Chalela, Roberto, Masuda, Ken, Ulivi, Paola, Shen, Kai, Shao, Qianwen, Xu, Jiali, Liu, Lianke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
iMDT Corner
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469170/
https://www.ncbi.nlm.nih.gov/pubmed/36111030
http://dx.doi.org/10.21037/atm-22-3582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469170/
https://www.ncbi.nlm.nih.gov/pubmed/36111030
http://dx.doi.org/10.21037/atm-22-3582

Ejemplares similares